| Tlou Energy Limited (TOU) ORDINARY FULLY PAID |
Energy |
$21 |
Application for quotation of securities - TOU
|
30 Aug 2024 9:30AM |
$0.034 |
$0.016 |
fallen by
52.94%
|
|
| Regal Investment Fund (RF1) ORDINARY UNITS FULLY PAID |
Financials |
$604 |
Update - Notification of buy-back - RF1
|
30 Aug 2024 9:29AM |
$3.190 |
$2.820 |
fallen by
11.60%
|
|
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$36 |
Appendix 4G and Corporate Governance Statement
|
30 Aug 2024 9:29AM |
$1.770 |
$0.325 |
fallen by
81.64%
|
|
| Tryptamine Therapeutics Limited (TYP) ORDINARY FULLY PAID |
Health Care |
$50 |
Appendix 4E Preliminary Final Report
|
30 Aug 2024 9:29AM |
$0.020 |
$0.036 |
risen by
80%
|
|
TYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from ordinary activities increased by 50493.6% to $985,057.
- Loss from ordinary activities after tax attributable to owners increased by 96.1% to $11,479,188.
- No dividends were paid, recommended, or declared during the current financial period.
- Acquisition of Tryp Therapeutics Inc and subsequent readmission to ASX.
- Net tangible assets per ordinary security improved to 0.44 cents from -4.65 cents.
- Company undertook a public offer of shares, raising $6,500,000.
- The financial statements reflect a 10-month period due to the change in accounting period.
- Significant increase in share-based payment expenses and transaction costs due to the reverse listing.
- Total expenses for the period were $12,464,245 compared to $5,856,585 in the previous period.
- Audit of the annual financial report is in process and not expected to be disputed or qualified.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$36 |
FY24 Results Announcement
|
30 Aug 2024 9:29AM |
$1.770 |
$0.325 |
fallen by
81.64%
|
|
LTP - Price-sensitive ASX Announcement
Full Release
Key Points
- LTR Pharma completed its IPO on December 11, 2023, raising AU$7 million.
- Company's shares commenced trading on the ASX under the ticker code ASX:LTP.
- As of June 30, 2024, LTR Pharma maintained a cash balance of $3.10 million.
- Completed a $10.5M placement to support key clinical and commercial milestones.
- Conducted a pivotal pharmacokinetic clinical study of SPONTAN nasal spray.
- SPONTAN showed rapid absorption and faster onset of action compared to oral PDE5 inhibitors.
- No serious adverse events were observed with SPONTAN.
- LTR Pharma completed critical manufacturing validation steps for SPONTAN.
- Secured a global Co-Development Agreement with Aptar Pharma to support SPONTAN's commercialization.
- SPONTAN prescribed under the TGA early access schemes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Resonance Health Limited (RHT) ORDINARY FULLY PAID |
Health Care |
$18 |
Full Year Results
|
30 Aug 2024 9:29AM |
$0.052 |
$0.040 |
fallen by
23.08%
|
|
RHT - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue of $8.6M, an increase of 95% from the prior period
- Normalised EBITDA of $0.69M, up 183% from the prior period
- Net positive operating cashflow of $1.39M, an increase of 983% from the prior period
- Earnings Per Share (EPS) increased to 0.04 CPS
- New clinical trial invoiced $3.85M during the period with $2.48M balance to be invoiced in FY25
- Completed acquisition of TrialsWest with a new trial site opened in August 2024
- Received R&D tax rebate of $796K
- Net Cash position of $3.68M with $6.85M cash at bank
- Strong growth expected in FY25 from clinical trials and SaMD revenues
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| IODM Limited (IOD) ORDINARY FULLY PAID |
Information Technology |
$80 |
Appendix 4E Annual Report to shareholders
|
30 Aug 2024 9:29AM |
$0.175 |
$0.130 |
fallen by
25.71%
|
|
IOD - Price-sensitive ASX Announcement
Full Release
Key Points
- IODM limited operational revenue increased by 67% in FY2024 due to a commercial partnership with Convera.
- Revenue from the UK education sector saw a 195% increase from $366K in FY2023 to $1.08M in FY2024.
- A new revenue share agreement with Convera was implemented, providing IODM with 25% of all FX revenues from onboarded universities and 30% from new universities.
- The agreement guarantees a minimum payment of GBP150,000 per month to IODM.
- IODM raised $800,000 through a share placement on 11 March 2024 to enhance onboarding capabilities and augment sales and technical teams.
- The company incurred a net loss after tax of $3,105,765 in FY2024.
- IODM had a net cash outflow from operating activities of $2,442,258 in FY2024.
- The company executed significant onboarding of additional universities, especially in the UK education sector.
- IODM completed a share placement on 8 August 2024 raising $1,710,375.
- IOPM's board is undergoing transformation to ensure compliance and governance obligations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 5G Networks Limited (5GN) ORDINARY FULLY PAID |
Information Technology |
$43 |
Notification of cessation of securities - 5GN
|
30 Aug 2024 9:28AM |
$0.150 |
$0.145 |
fallen by
3.33%
|
|
| Raiz Invest Limited (RZI) ORDINARY FULLY PAID |
Financials |
$67 |
Raiz Share Purchase Plan
|
30 Aug 2024 9:27AM |
$0.400 |
$0.640 |
risen by
60%
|
|
RZI - Price-sensitive ASX Announcement
Full Release
Key Points
- Raiz Invest Limited announced a Share Purchase Plan (SPP) to allow eligible shareholders to purchase up to $30,000 of new shares without incurring brokerage or other transaction costs.
- The SPP aims to raise up to $2 million and follows the successful institutional placements which raised $3 million.
- New SPP shares are offered at the lower of $0.41 per share or a 2.5% discount to the volume-weighted average price (VWAP) of Raiz Invest shares traded on ASX during the five trading days up to the SPP closing date.
- The proceeds from the SPP will be used for strategic opportunities, including building a bespoke AI language model, product innovation, and potential future mergers and acquisitions.
- Participation in the SPP is voluntary and is available to shareholders with addresses in Australia or New Zealand who held shares as of 23 August 2024.
- Shares issued under the SPP will rank equally with existing shares.
- The SPP is not available to shareholders in the United States or those holding shares on behalf of persons in the United States.
- Applications for the SPP must be received by 5:00pm on 13 September 2024, and shares will be issued on 20 September 2024.
- Raiz Invest reserves the right to scale back applications and any oversubscription funds will be refunded.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$36 |
Appendix 4E and Annual Financial Report
|
30 Aug 2024 9:27AM |
$1.770 |
$0.325 |
fallen by
81.64%
|
|
LTP - Price-sensitive ASX Announcement
Full Release
Key Points
- LTR Pharma Limited successfully completed an IPO and listed on the Australian Securities Exchange under the ticker ASX: LTP in December 2023.
- The company's flagship product, SPONTAN, is an innovative nasal spray treatment for Erectile Dysfunction (ED) designed to work within 10 minutes.
- SPONTAN has demonstrated a significant improvement over oral treatments in clinical studies, achieving maximum concentration levels in an average of 12 minutes.
- LTR Pharma's financial results for the year ended 30 June 2024 show a significant increase in revenue but also a substantial net loss.
- The company raised $7 million through its IPO to support R&D activities and the commercialisation pathway of SPONTAN.
- LTR Pharma completed its pivotal pharmacokinetic clinical study for SPONTAN, showing rapid absorption and faster onset of action compared to oral PDE5 inhibitors.
- The company achieved manufacturing validation for SPONTAN, meeting essential FDA requirements for a pivotal clinical study.
- LTR Pharma's Chief Scientific Advisor, Professor Eric Chung, was awarded the ISSM Emil Tanagho Prize for innovative research in ED treatments.
- The company's net tangible asset per ordinary share increased from 1.487 cents in 2023 to 2.109 cents in 2024.
- LTR Pharma completed a $10.5 million share placement and signed a Global Co-Development agreement post the financial year-end.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Livium Ltd (LIT) ORDINARY FULLY PAID |
Industrials |
$17 |
Sustainability Report
|
30 Aug 2024 9:26AM |
$0.021 |
$0.010 |
fallen by
52.38%
|
|
| Future Generation Global Limited (FGG) ORDINARY FULLY PAID |
Financials |
$567 |
Appendix 4D and Financial Report
|
30 Aug 2024 9:25AM |
$1.330 |
$1.420 |
risen by
6.77%
|
|
FGG - Price-sensitive ASX Announcement
Full Release
Key Points
- True and fair view of the company’s financial position as at 30 June 2024.
- Compliance with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.
- Review conducted in accordance with ASRE 2410 Review of a Financial Report Performed by the Independent Auditor.
- Independence of the Company in accordance with the auditor independence requirements of the Corporations Act 2001.
- Directors are responsible for the preparation of the half-year financial report.
- Total comprehensive income for the period ended 30 June 2024.
- Financial performance overview includes trading revenue, cost of sales, gross profit, and other income and expenses.
- Balance sheet items cover working capital, property, plant and equipment, and provisions.
- Capital structure and risk management include credit facilities, issued capital, and financial risk management.
- Group structure details subsidiaries, deed of cross guarantee, and non-controlling interests.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ImExHS Limited (IME) ORDINARY FULLY PAID |
Health Care |
$18 |
Investor Presentation - 1H FY24 Results
|
30 Aug 2024 9:24AM |
$0.500 |
$0.340 |
fallen by
32%
|
|
IME - Price-sensitive ASX Announcement
Full Release
Key Points
- 1H FY24 Underlying EBITDA of $0.3m, down $0.2m vs pcp
- 1H FY24 Revenue of $13.8m, 57% up on pcp and 32% up on constant currency
- Annualised Recurring Revenue of $29.6m, up 21% vs pcp
- Significant working capital consumption with net cash used in operating activities of $1.5m
- Enterprise software contract renewal with Colsubsidio contributing $575,000 in ARR
- New contract in Colombia valued at $790,000 for biomedical equipment and AQUILA Enterprise
- Strong sales pipeline for IMEXHS Cloud and Enterprise radiology solutions
- Software development program on time and on budget
- Radiology profit improvement through renegotiation of contracts
- New radiology services contract in Colombia with expected ARR of $564,000
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| FBR Ltd (FBR) ORDINARY FULLY PAID |
Industrials |
$34 |
Preliminary Final Report
|
30 Aug 2024 9:24AM |
$0.037 |
$0.006 |
fallen by
83.78%
|
|
FBR - Price-sensitive ASX Announcement
Full Release
Key Points
- FBR Ltd released its Preliminary Final Report for the financial year.
- Revenue for the year was $1.67 million, compared to $1.09 million in the previous year.
- Net loss after tax was $9.59 million, compared to $5.12 million in the previous year.
- Total comprehensive loss for the year was $9.47 million.
- Cash and cash equivalents at year-end were $3.76 million.
- The company focused on commercialization of its Hadrian X technology.
- Significant progress was made in the construction and application of Hadrian X for bricklaying.
- FBR Ltd has engaged in several partnerships and pilot programs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Complii Fintech Solutions Ltd (CF1) ORDINARY FULLY PAID |
Information Technology |
$14 |
Issue of Shares
|
30 Aug 2024 9:24AM |
$0.023 |
$0.024 |
risen by
4.35%
|
|
| Swift Networks Group Limited (SW1) ORDINARY FULLY PAID |
Communication Services |
$11 |
Annual Results Presentation
|
30 Aug 2024 9:24AM |
$0.015 |
$0.012 |
fallen by
20%
|
|
SW1 - Price-sensitive ASX Announcement
Full Release
Key Points
- $2.4 million Enterprise EBITDA
- $15.0 million annualised Subscription Revenue
- Generating cash from operations
- Low market cap – 50% of Revenue
- Turn-around story
- Inhouse development team
- Aged Care market has strong growth
- Enviable customer base (path to market)
- New SaaS product under development
- New Platform/Tech brings access to new aligned markets
- Worldwide market opportunities for Swift Access Engagement SaaS
- Swift Networks Group Limited operates in the Aged Care and Mining sectors
- Capital Structure with 647 million shares on issue
- Market Capitalisation of $9.7 million
- Debt of $7.4 million as of 30 June 2024
- Major shareholders include Sofoulis Holdings Pty Ltd and JP Morgan Nominees Australia Pty Ltd
- Goals include growing subscription earnings, securing large provider Aged Care subscription contracts, and launching Swift Access into new markets
- Swift Access Aged Care Engagement (ACE) product to be launched in Australian Aged Care in 2024
- Strong growth potential in Mining and Aged Care sectors
- Focus on reducing debt and improving margins
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ImExHS Limited (IME) ORDINARY FULLY PAID |
Health Care |
$18 |
IMEXHS Reports 1H FY24 Results
|
30 Aug 2024 9:23AM |
$0.500 |
$0.340 |
fallen by
32%
|
|
IME - Price-sensitive ASX Announcement
Full Release
Key Points
- 1HFY24 revenue of $13.8m, up 57% vs pcp; up 32% on a constant currency basis.
- 1HFY24 Underlying EBITDA of $0.3m; down 47% vs pcp.
- Annualised Recurring Revenue (ARR) of $29.6m, up 21% vs pcp.
- Debt of $0.9m at 30 June 2024, down from $1.3m at 31 Dec 2023.
- Cash of $1.9m at 30 June 2024, down from $2.4m at 31 Dec 2023.
- Enterprise software contract renewal with Colsubsidio, expected to contribute $575,000 in ARR.
- New one-off contract secured in Colombia for $790,000.
- New radiology services contract in Colombia, expected to contribute $564,000 in ARR.
- Sales pipeline for both IMEXHS Software and Radiology services remains strong.
- IMEXHS Enterprise and Cloud have a total of 518 installations worldwide.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Complii Fintech Solutions Ltd (CF1) ORDINARY FULLY PAID |
Information Technology |
$14 |
Application for quotation of securities - CF1
|
30 Aug 2024 9:23AM |
$0.023 |
$0.024 |
risen by
4.35%
|
|
| Hubify Limited (HFY) ORDINARY FULLY PAID |
Communication Services |
$4 |
Notification of cessation of securities - HFY
|
30 Aug 2024 9:23AM |
$0.012 |
$0.008 |
fallen by
33.33%
|
|
| WCM Quality Global Growth Fund (Managed Fund) (WCMQ) |
Financials |
$401 |
Quarterly portfolio disclosure as at 30 June 2024
|
30 Aug 2024 9:22AM |
$8.700 |
$11.070 |
risen by
27.24%
|
|
| EDU Holdings Limited (EDU) ORDINARY FULLY PAID |
Consumer Discretionary |
$28 |
1H24 - Half-Year Results Presentation
|
30 Aug 2024 9:22AM |
$0.090 |
$0.185 |
risen by
105.56%
|
|
EDU - Price-sensitive ASX Announcement
Full Release
Key Points
- Group revenue increased by 64% with Ikon up 88% and ALG up 37%
- EBITDA improved significantly to $2.3 million from $0.2 million
- Statutory net profit after tax was $28,000, an improvement of $1.6 million
- Ikon enrolments grew by 85% and continued growth into Trimester 2, 2024
- ALG enrolments rebounded with a 24% increase in 1H24
- Operating leverage was evident with an 8 percentage points improvement in EBITDA margin
- Strategic positioning in response to regulatory changes likely to affect future enrolments
- Strong cash balance with net cash increasing by $5.2 million to $6.3 million
- Focus on student volume growth, product development, operational efficiency, and preparation for proposed caps on new overseas student commencements
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Chariot Corporation Ltd (CC9) ORDINARY FULLY PAID |
Materials |
$8 |
Chariot & Mustang Lithium LLC Update
|
30 Aug 2024 9:22AM |
$0.105 |
$0.071 |
fallen by
32.38%
|
|
CC9 - Price-sensitive ASX Announcement
Full Release
Key Points
- Chariot holds a 24.1% ownership interest in Mustang Lithium LLC.
- Mustang is repossessing the Horizon and Halo lithium projects.
- Pan American Energy Corp. and POWR Lithium Corp. terminated their property option agreements due to market conditions.
- Mustang raised USD 250,000 through convertible notes for maintenance fees.
- Horizon Lithium Project has an Indicated category of 1.3 Mt LCE and an Inferred category of 8.8 Mt LCE.
- Chariot’s core projects include Black Mountain and Resurgent Projects.
- Chariot holds interests in multiple exploration pipeline projects in Wyoming and Nevada.
- Property option agreements with Pan American Energy and POWR are being terminated.
- Pan American Energy reported a maiden Mineral Resource estimate for Horizon Lithium Project.
- Mustang's liquid assets include shares in Pan American Energy, POWR, and other companies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Resonance Health Limited (RHT) ORDINARY FULLY PAID |
Health Care |
$18 |
Appendix 4E & Annual Report to Shareholders
|
30 Aug 2024 9:22AM |
$0.052 |
$0.040 |
fallen by
23.08%
|
|
RHT - Price-sensitive ASX Announcement
Full Release
Key Points
- Resonance Health Limited is an Australian healthcare technology and services company.
- The company provides quantitative imaging assessments globally for disease management and clinical trials.
- Record revenues of $8.6M in FY24, a 95% increase from FY23.
- Significant clinical trial contract worth $6.33M with a major global pharma company.
- Acquisition of TrialsWest, a clinical research center.
- Development of non-invasive MRI liver fibrosis assessment tool.
- Strong performance in North America, Asia Pacific, and the UK.
- Expansion into the clinical trial ecosystem with CRO services.
- No dividends were paid, recommended, or declared during the financial years.
- Positive operating cash flow of $1.39M up from a loss in FY23.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ImExHS Limited (IME) ORDINARY FULLY PAID |
Health Care |
$18 |
Half Yearly Report and Accounts
|
30 Aug 2024 9:22AM |
$0.500 |
$0.340 |
fallen by
32%
|
|
IME - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from ordinary activities increased by 56.6% to $13,784,973.
- Loss after tax decreased by 33.8% to $1,518,459.
- No dividends were paid, recommended, or declared.
- Net tangible assets per ordinary security were 15.26 cents, down from 20.25 cents.
- Joint operation entered on 24 August 2023 with a 75% interest for radiology services with Colombia's National Police Hospital.
- Unmodified audit opinion with emphasis on going concern issued.
- Group’s EBITDA was a profit of $0.03m compared to EBITDA loss of $1.0m for 1H FY23.
- ARR of $29.6m as at 30 June 2024, up 21% vs pcp.
- Significant revenue growth in both software and radiology services segments.
- Revenue growth was driven by recurring revenue contracts accounting for 95% of revenue.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Livium Ltd (LIT) ORDINARY FULLY PAID |
Industrials |
$17 |
Corporate Governance Statement
|
30 Aug 2024 9:21AM |
$0.021 |
$0.010 |
fallen by
52.38%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
